FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

List Robin 		2. Issuer Name and Ticker or Trading Symbol

REMEDENT, INC. [ REMI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
_____ Officer (give title below)      __ X __ Other (specify below)
Former Officer and Director
(Last)          (First)          (Middle)

XAVIER DE COCKLAAN 42 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/10/2008
(Street)

DEURLE, C9 9831
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   12/10/2008     D (1) (2)    723000   (1) (2) D (1) (2) $0   (1) (2) 9827   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  In connection with that certain restructuring Plan conducted by the Issuer relating to the buyout of its Over-The-Counter ("OTC") business, the Reporting Person purchased 50% interest in Remedent OTC BV, a Dutch holding company and a wholly owned subsidiary of the Issuer ("Remedent OTC") in exchange for 723,000 restricted shares of common stock of the Issuer held by the Reporting Person ("Exchanged Shares"), pursuant to a Share Purchase Agreement on December 10, 2008. The Exchanged Shares were valued at $1.15 per share, based on the average of the 52 week high and low bid, for an aggregate value of $831,450. (Continued on Footnote #2)
( 2)  As a result, the Reporting Person resigned from certain of his officer and director positions maintained with the Issuer and other subsidiary to equally own with the Issuer 50% of Remedent OTC, with the Issuer currently controlling Remedent OTC through its board representations pursuant to the terms of a certain Voting Agreement entered into by the Issuer and Reporting Person concurrent with the Share Purchase Agreement. Terms and conditions of the transactions between the Issuer and Reporting Person and the OTC business restructuring are more fully described in the Issuer's Form 8-K filed with the SEC on December 16, 2008.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
List Robin
XAVIER DE COCKLAAN 42
DEURLE, C9 9831


Former Officer and Director

Signatures
/s/ Robin List 12/16/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Elysee Development (PK) (USOTC:ASXSF)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Elysee Development (PK) Charts.
Elysee Development (PK) (USOTC:ASXSF)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Elysee Development (PK) Charts.